Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr 29;7(8):101437.
doi: 10.1016/j.jhepr.2025.101437. eCollection 2025 Aug.

Transjugular diagnostic procedures in hepatology: Indications, techniques and interpretation

Affiliations
Review

Transjugular diagnostic procedures in hepatology: Indications, techniques and interpretation

Dominik Bettinger et al. JHEP Rep. .

Abstract

Measurement of the hepatic venous pressure gradient (HVPG) and transjugular liver biopsy have emerged as important tools in clinical hepatology. Measurement of HVPG is considered the gold standard for detecting clinically significant portal hypertension, with an HVPG of ≥10 mmHg being the key prognostic threshold in patients with compensated advanced chronic liver disease (cACLD; compensated cirrhosis). A transjugular liver biopsy can be obtained within the same procedure and may be preferred over percutaneous liver biopsy in patients with coagulopathy, ascites and/or significant obesity. Endoscopic ultrasound-guided procedures are currently under investigation and require standardisation. This article summarises critical technical aspects of HVPG measurements and transjugular liver biopsy and provides a detailed overview of their current role in the context of emerging non-invasive tests and endoscopic approaches.

Keywords: Cirrhosis; HVPG; PSVD; hepatic venous pressure gradient; minimally invasive; portal hypertension; porto-sinusoidal vascular disorder; transjugular liver biopsy.

PubMed Disclaimer

Conflict of interest statement

DB: Lecture fees/consulting: W. L. Gore & Associates GmbH, Travel grant: Gilead Science. AB: Consulting: Boehringer-Ingelheim; lecture fees: W. L. Gore & Associates GmbH; GE Healthcare; Hologic. MM: Speaker and/or consultant and/or advisory board member for AbbVie, Collective Acumen, Gilead, Echosens, Ipsen, Takeda, and W. L. Gore & Associates; travel support from AbbVie and Gilead. CR: Consulting: Boehring-Ingelheim, lecture fees: W. L. Gore & Associates GmbH, Falk Foundation, Bristol-Myers Squibb. EZ: lecture fees: Abbvie, Gilead, Dr. Falk Pharma; travel grants: Abbvie, Gilead, W.L. Gore& Associates; advisory: Bentley InnoMed. TB: received consulting fees from Intercept/Advanz Pharma, Grifols, and Sobi; honoraria for lectures, presentations, or educational events from Falk Foundation, CSL Behring, Merck, Gilead, Intercept/Advanz Pharma, and Gore; travel support from Gilead. CE: Advisory: Boehringer-Ingelheim, Albireo, Lecture fees: Albireo, Gilead. VF: Advisory: Astra Zeneca, ADVITOS, Lecture fees: CSL-Behring, ADVITOS, Astra Zeneca, Merz. PAR: lecture fees: Pfizer, BMS, CSL Behring, CSL Seqirus, AstraZeneca; Advisory Board: Gilead, ADVANZ, Pfizer, travel support AbbVie, Ipsen. MS: lecture fees/consulting: Falk Foundation e.V., W. L. Gore & Associates, Bentley InnoMed GmbH. AZ: Lecture fees/consulting: CLS Behringer, Lecture fees: W. L. Gore & Associates GmbH, Falk Foundation, CML: consulting fees from Abbvie, AstraZeneca, Boston Scientific, CSL Behring, Eisai, Falk, Gilead, Norgine, Roche, Shionogi, and Sobi; honoraria for lectures, presentations, or educational events from Abbvie, AstraZeneca, Boston Scientific, CSL Behring, Gore, Eisai, Falk, and Norgine. TR: received grant support from Abbvie, Boehringer Ingelheim, Gilead, Intercept/Advanz Pharma, MSD, Myr Pharmaceuticals, Philips Healthcare, Pliant, Siemens and W. L. Gore & Associates; speaking honoraria from Abbvie, Gilead, Intercept/Advanz Pharma, Roche, MSD, W. L. Gore & Associates; consulting/advisory board fee from Abbvie, Astra Zeneca, Bayer, Boehringer Ingelheim, Gilead, Intercept/Advanz Pharma, MSD, Resolution Therapeutics, Siemens; and travel support from Abbvie, Boehringer Ingelheim, Dr. Falk Pharma, Gilead and Roche. RK: received consulting fees from Boston Scientific, Bristol Myers Squibb, Guerbet, Roche, and Sirtex and lecture fees from Astra Zeneca, BTG, Eisai, Guerbet, Ipsen, Roche, Siemens, Sirtex, MSD Sharp & Dohme and is on the data safety monitoring board of the ABC HCC Trial. Furthermore, he serves as the Chair of the Audit and Standards Subcommittee of the European Society of Radiology. All of these roles are not related to this project. JB: Consultant to AstraZeneca, Boehringer Ingelheim, Novo Nordisk and Resolution Therapeutics. MD: Lecture fees/consulting: Sanofi-Aventis, Ipsen Pharma, Allpha Sigma Pharma, Takeda Pharmaceuticals, Falk Foundation, Mainz Biomed GmbH; Travel grant: Gilead Science, Falk Foundation. Please refer to the accompanying ICMJE disclosure forms for further details.

Figures

Image 1
Graphical abstract
Fig. 1
Fig. 1
Concept of HVPG measurement. Sinusoidal portal hypertension, as typically seen in patients with viral and ALD-associated cirrhosis, is characterised by interruption of inter-sinusoidal channels. If a balloon catheter is wedged in the hepatic vein, a static pressure column is transmitted into the portal vein. As the inter-sinusoidal channels are closed, the pressure cannot be buffered. Therefore, WHVP equilibrates the PP and HVPG adequately depicts the PSG (A). In patients with non-cirrhotic portal hypertension or with increased pre-sinusoidal resistance, the inter-sinusoidal channels are open and can buffer the static pressure column. In this situation the WHVP underestimates the PP (B). Adapted from. Created with biorender.com. FHVP, free hepatic vein pressure, IVC, inferior vena cava; PP, portal pressure; PSG, portosystemic gradient; WHVP, wedged hepatic vein pressure.
Fig. 2
Fig. 2
Venography during HVPG measurement. (A) Confirmation of the wedge (occlusion) position in the right hepatic vein with the balloon inflated by injecting contrast medium. (B) Veno-venous communication vessels. HVPG, hepatic venous pressure gradient.
Fig. 3
Fig. 3
Pressure recording of FHVP, WHVP, FHVP ret., IVC pressure, and RAP. Pressure recording of the FHVP (FHVP1-3), WHVP (WHVP1-3), the optional retracted FHVP (max. 2-3 cm from the junction with the IVC; FHVP ret.), the IVCP and RAP. The “retracted” FHVP is better for calculating the hepatic venous pressure gradient, if the WHVP is measured far peripherally. FHVP, free hepatic vein pressure; FHVP ret., retracted FHVP; IVC, inferior vena cava; IVCP, IVC pressure; RAP, right arterial pressure; WHVP, wedged hepatic vein pressure.
Fig. 4
Fig. 4
Positioning of the catheter in the right hepatic vein followed by pushed core liver biopsy. (A,B) Confirmation of the position of the introduction catheter in the right hepatic vein by injecting contrast medium (A), followed by the pushed core liver biopsy (B). (C) A schematic description of TJLB is provided.

References

    1. Clinical practice guidelines of the European association for the study of the liver - advancing methodology but preserving practicability. J Hepatol. 2019;70:5–7. - PubMed
    1. Albillos A., Bañares R., González M., et al. The extent of the collateral circulation influences the postprandial increase in portal pressure in patients with cirrhosis. Gut. 2007;56:259–264. - PMC - PubMed
    1. Zhang H., Yang L., Yu Z., et al. Impact of fentanyl analgesia on the accuracy of HVPG measurements in patients with cirrhosis: a prospective, multicenter study. Hepatol Commun. 2023;7 - PMC - PubMed
    1. Steinlauf A.F., Garcia-Tsao G., Zakko M.F., et al. Low-dose midazolam sedation: an option for patients undergoing serial hepatic venous pressure measurements. Hepatol Baltim Md. 1999;29:1070–1073. - PubMed
    1. de Franchis R., Bosch J., Garcia-Tsao G., R, et al. Baveno VII - renewing consensus in portal hypertension. J Hepatol. 2022;76:959–974. - PMC - PubMed